Related Experiment Video

Updated: Aug 13, 2026

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy
04:05

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy

Published on: August 22, 2025

Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind

G Bianchi Porro1, M Lazzaroni, M Petrillo

  • 1Gastro-intestinal Unit, L. Sacco University Hospital, Milano, Italy.

Italian Journal of Gastroenterology and Hepatology
|June 6, 1998
PubMed
Abstract

Insights

Omeprazole significantly reduced NSAID-induced ulcers compared to placebo. This proton pump inhibitor offers effective prevention for patients at risk of gastroduodenal damage from nonsteroidal anti-inflammatory drugs.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin, diclofenac, and ketoprofen are commonly used for arthritis.
  • NSAID use can lead to significant gastroduodenal lesions, including ulcers, impacting patient health and treatment adherence.

Purpose of the Study:

  • To evaluate the efficacy of omeprazole (20 mg daily) versus placebo in preventing NSAID-induced gastroduodenal lesions.
  • To compare the incidence of gastric and duodenal ulcers in patients receiving NSAIDs with or without omeprazole prophylaxis.

Main Methods:

  • A double-blind, randomized study involving 114 patients with arthritic disorders requiring NSAIDs.
  • Patients received either omeprazole (20 mg daily) or placebo for three weeks, with gastroduodenal mucosa damage assessed endoscopically using a 0-4 scale.

Main Results:

  • Omeprazole prophylaxis resulted in a higher proportion of patients with normal gastroduodenal mucosa (46%) compared to placebo (35%), though not statistically significant (p ns).
  • A significant reduction in gastric ulcers was observed in the omeprazole group (0%) compared to the placebo group (12%) (p < 0.01).
  • Fewer patients in the omeprazole group experienced dyspeptic symptoms (10%) compared to the placebo group (29%) (p ns).

Conclusions:

  • Omeprazole (20 mg daily) is an effective prophylactic treatment for preventing NSAID-associated gastric ulcers.
  • The findings support the use of omeprazole in patients at risk of developing NSAID-induced gastroduodenal ulcers.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...